Molecular structure of CP-91149, CAS Number: 186392-40-5
CP-91149 (CAS 186392-40-5)
See product citations (1)
Alternate Names:
5-Chloro-N-[(1S,2R)-3-(dimethylamino)-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-1H-indole-2-carboxamide
Application:
CP-91149 is a selective glycogen phosphorylase (GP) inhibitor
CAS Number:
186392-40-5
Purity:
≥97%
Molecular Weight:
399.87
Molecular Formula:
C21H22ClN3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
With its remarkable selectivity, CP-91149 stands out as a potent inhibitor of glycogen phosphorylase (GP). In the presence of glucose, it demonstrates an impressive IC50 value of 0.13 μM, effectively impeding GP activity. However, its potency decreases when glucose is absent, showing 5- to 10-fold lower inhibitory efficacy. This distinctive behavior highlights the dependency of CP-91149′s effectiveness on the presence of glucose.
CP-91149 (CAS 186392-40-5) References
- Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. | Curtis, M., et al. 2019. Cell Metab. 29: 141-155.e9. PMID: 30174305
- Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells. | Barot, S., et al. 2019. Exp Cell Res. 381: 288-300. PMID: 31128107
- Revisiting Glycogen in Cancer: A Conspicuous and Targetable Enabler of Malignant Transformation. | Khan, T., et al. 2020. Front Oncol. 10: 592455. PMID: 33224887
- Neutrophils Fuel Effective Immune Responses through Gluconeogenesis and Glycogenesis. | Sadiku, P., et al. 2021. Cell Metab. 33: 411-423.e4. PMID: 33306983
- Three-dimensional tissue-engineered human skeletal muscle model of Pompe disease. | Wang, J., et al. 2021. Commun Biol. 4: 524. PMID: 33953320
- Optimization and Validation of an In Vitro Standardized Glycogen Phosphorylase Activity Assay. | Rocha, S., et al. 2021. Molecules. 26: PMID: 34361792
- An In Silico and an In Vitro Inhibition Analysis of Glycogen Phosphorylase by Flavonoids, Styrylchromones, and Pyrazoles. | Rocha, S., et al. 2022. Nutrients. 14: PMID: 35057487
- Lung adenocarcinoma-derived vWF promotes tumor metastasis by regulating PHKG1-mediated glycogen metabolism. | Gu, J., et al. 2022. Cancer Sci. 113: 1362-1376. PMID: 35150045
- Metabolic Reprogramming Mediates Delayed Apoptosis of Human Neutrophils Infected With Francisella tularensis. | Krysa, SJ. and Allen, LH. 2022. Front Immunol. 13: 836754. PMID: 35693822
- Glucometabolic reprogramming: From trigger to therapeutic target in hepatocellular carcinoma. | Xia, H., et al. 2022. Front Oncol. 12: 953668. PMID: 35912218
- Metabolic alterations and mitochondrial dysfunction underlie hepatocellular carcinoma cell death induced by a glycogen metabolic inhibitor. | Barot, S., et al. 2022. Biochem Pharmacol. 203: 115201. PMID: 35926650
- Repurposing an Antiepileptic Drug for the Treatment of Glioblastoma. | Yadav, A., et al. 2022. Pharm Res. 39: 2871-2883. PMID: 36195821
- In Vitro Antidiabetic, Antioxidant, and Prebiotic Activities of the Chemical Compounds Isolated from Guizotia abyssinica. | Elbermawi, A., et al. 2022. Antioxidants (Basel). 11: PMID: 36552690
Inhibitor of:
C230052I12Rik, G6Pase-α, G6Pase-β, G6PT, Glut2, glycogen synthase 1, Glycogenin (GYG), H6PD, PEPCK-C, PYGB, PYGL, PYGM, and sMtCK.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CP-91149, 5 mg | sc-396026A | 5 mg | $163.00 | |||
CP-91149, 10 mg | sc-396026 | 10 mg | $204.00 | |||
CP-91149, 25 mg | sc-396026B | 25 mg | $398.00 | |||
CP-91149, 50 mg | sc-396026C | 50 mg | $500.00 | |||
CP-91149, 100 mg | sc-396026D | 100 mg | $714.00 |